RENOVA™ THERAPEUTICS - Key Persons
Vijay Mahant (MS, Ph.D., Loughborough University, UK) is a visionary and a pioneer scientist in the healthcare industry with entrepreneurship qualities that spans more than three decades in genetic diseases, infectious diseases, and precision medicine (oncology, cardiovascular diseases, neuropsychiatry & pain management). Vijay Mahant's focus over the last decade has been on therapeutics (small drugs including biopharmaceuticals and cellular), drug delivery, and therapeutic devices. His pioneering work in diagnostics, as exemplified by ultra-sensitive tests in thyroid endocrinology and prostate cancer, has been a "game changer" in endocrinology and oncology. The products developed under his leadership have generated hundreds of millions of dollars in revenue. He is a passionate and a decisive leader who has mentored several young entrepreneurs in the biotech industry. Vijay Mahant brings in vast experience and wealth of knowledge including skills ranging from research and development including numerous FDA cleared & CE Marked products, fund raising, IPOs, acquisitions, licensing with conglomerates and major institutes, manufacturing, clinical trials and intellectual property management. He has held senior positions at Nicholas Institute/ Quest, and executive positions at Qualigen, and AGI. He is a founder and/or co-founder of diagnostic companies including MediLite Diagnostika and a former executive at an oncology company. He serves on the SAB/MAB of young oncology companies such as Trutino Biosciences and an oncology hospital. Vijay Mahant is on the Board of Directors of Renova Therapeutics and serves as the CEO. Vijay Mahant has authored and/or co-authored publications in peer-reviewed science and/or medical journals and contributed chapters in books. He has 32 issued international patents in health care. He launched a section entitled "The Eco-system of Translational Medicine" as the Section Editor of the Journal of Translational Medicine.
William Davidson has served as a director of six public companies and more than ten private
companies. He has served as chairman for one public and multiple private companies. He has
Job Titles:
- Co - Founder
- Director
- Member of the Executives and Board of Directors
Dr. H. Kirk Hammond, M.D. serves as principle scientific advisor to the Company and is a cardiologist. Dr. Hammond has devoted his career to the study of heart diseases. Dr. Hammond co-founded Collateral Therapeutics, and subsequently co-founded Renova Therapeutics based on data from his laboratory indicating the promise of AC6 gene transfer for Heart Failure (HF). He is currently Professor of Medicine at University of California San Diego and a cardiologist at VA San Diego. He received training in cardiovascular research and clinical cardiology at University of California San Diego and joined the School of Medicine faculty in 1987. Dr. Hammond's research focuses on mechanisms and treatments of human cardiovascular diseases using gene transfer. His laboratory employs molecular and cellular biology and integrative physiological techniques in translational studies designed to have an impact on the treatment of chronic heart disease. His pioneering work led to the first Phase 2 clinical trial of gene transfer for patients with heart disease. He is a past chairman of the Cardiovascular Section of the American Society of Gene and Gene Therapy. Dr. Hammond's research laboratory at the University of California, San Diego and VA San Diego currently is funded for basic and translational research by the NIH and Veterans Administration. Hammond was a 2017 recipient of the Veterans Affairs William S. Middleton Award for Outstanding Achievement in Biomedical Research. In 2020, Hammond received the VA Biomedical Research & Development Senior Clinician Scientist Investigator Award.
Job Titles:
- Chairman of the Executives and Board of Directors
- Chief Executive Officer
Michael A. Torres is the Chief Executive Officer of Adelante Capital Management, an employee and minority-owned SEC-registered Investment Advisor. Adelante manages publicly traded real
Mr. Morgan Xu is the former Chairman and CEO of Vistage China. Vistage is the world's leading
Pierre Lecocq served for 20 years as CEO of a global leading automotive components company
with a manufacturing presence in 20 different countries. After the sale of the company, he